echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Bayer Verizikari is approved in the EU for the treatment of symptomatic chronic heart failure

    Bayer Verizikari is approved in the EU for the treatment of symptomatic chronic heart failure

    • Last Update: 2021-08-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On July 22, 2021, Bayer announced that the European Commission had approved the marketing authorization for Verquvo™ (2.


    Verizilq is a soluble guanylate cyclase stimulant for the treatment of adult patients with symptomatic chronic heart failure (after a decrease in ejection fraction, a recent decompensation event requiring intravenous therapy has stabilized)


    The lead investigator of the Phase III VICTORIA clinical trial, Charité Professor of Internal Medicine and Cardiology, Dr.


    Velixiqua has been approved by the U.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.